Cencora Sets Schedule for Q2 Fiscal 2026 Earnings Announcement
Cencora to Release Second Quarter Fiscal 2026 Results on May 6, 2026 Cencora, Inc. has officially announced the date and time for the release of its financial results for the second quarter of fiscal year 2026. The company will publish…
Alpha Cognition Secures U.S. Patent for ALPHA-1062 Targeting Traumatic Brain Injury Treatment
Alpha Cognition Secures U.S. Patent for ALPHA-1062 in Traumatic Brain Injury, Expanding Pipeline Potential Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The…
Alto Neuroscience Announces Phase 2 Topline Results for ALTO-101 and Pipeline Progress
Alto Neuroscience Shares Phase 2 Results for ALTO-101 and Refocuses Pipeline Strategy Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company dedicated to developing precision medicines for neuropsychiatric disorders, has released topline findings from its Phase 2 proof-of-concept (POC) study evaluating ALTO-101.…
Premier Radiology Services Expands Capabilities with Acquisition of Global Imaging Solutions
Premier Radiology Services Acquires Global Imaging Solutions to Expand Teleradiology and Subspecialty Expertise Premier Radiology Services (Premier) has announced the acquisition of Global Imaging Solutions (GLOBIS), a well-established teleradiology provider known for delivering subspecialty imaging interpretations to outpatient imaging centers…
FORE Biotherapeutics’ Plixorafenib Granted Breakthrough Therapy Designation
FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its…
Shionogi Completes Global Acquisition of RADICAVA Rights
Shionogi Strengthens Rare Disease Portfolio with Full Acquisition of RADICAVA (Edaravone) Shionogi & Co., Ltd. has officially completed the acquisition of all rights to RADICAVA (edaravone), marking a major milestone in the company’s strategic expansion into rare diseases. The transition…
Frontier Medicines Signs Exclusive Licensing Deal with LG Chem for First-in-Class p53 Y220C Activator FMC-220
Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd. for its novel oncology candidate FMC-220, a first-in-class covalent activator…
Mosaic Therapeutics appoints Dr Vince O’Neill, MD, as Head of R&D
Mosaic Therapeutics Strengthens Leadership with Appointment of Dr. Vince O’Neill as Head of R&D Mosaic Therapeutics, a clinical-stage oncology company focused on developing next-generation combination therapies, has announced the appointment of Dr. Vince O’Neill, MD, as its new Head of…
ENDRA Life Sciences Reports Q4 & Full-Year 2025 Results, Shares Business Update
ENDRA Life Sciences Reports 2025 Financial Results and Highlights Strategic Progress ENDRA Life Sciences Inc a company focused on advancing thermoacoustic biomarker imaging technology, has announced its financial results for the fourth quarter and full year ended December 31, 2025.…
Healthy Smiles 2.0 Focuses on Oral Care for California’s Older Adults
Healthy Smiles Never Gets Old 2.0: Advancing Oral Health for California’s Aging Population The Center for Oral Health has released Healthy Smiles Never Gets Old 2.0, a comprehensive updated report that examines the oral health status, challenges, and opportunities facing…
AHF Honors the Legacy of Global Health Leader and Diplomat Stephen Lewis
AHF Honors Stephen Lewis’ Global Health Legacy AIDS Healthcare Foundation (AHF) has paid tribute to the life and legacy of Stephen Lewis, a towering figure in global health diplomacy and a relentless champion in the fight against HIV His passing…
Sub-Q Bionics Secures $1.5M Pre-Seed Funding to Advance Innovative Lymphedema Treatment
Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Advance Breakthrough Lymphedema Technology Sub-Q Bionics, an emerging medical device company focused on transforming the treatment landscape for lymphedema, has successfully closed a $1.5 million pre-seed financing round. This milestone marks an…